<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Guillot-Delost M</submitter><funding>European Research Council</funding><pagination>e1179414</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5006899</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(7)</volume><pubmed_abstract>Thymic stromal lymphopoietin (TSLP) is an interleukin (IL)-7-like cytokine expressed by epithelial cells during allergic inflammation, and activating dendritic cells (DC). Its expression and functional role in cancer remain controversial. We conducted retrospective (n = 89), and prospective studies including patients with untreated primary head and neck squamous cell carcinoma (HNSCC). We found that TSLP was overexpressed by HNSCC tumor cells, and associated with a highly differentiated status. However, no significant difference in overall and recurrence-free survival was found between patients bearing a tumor with high and low TSLP levels, respectively. Surprisingly, there was no significant association between the levels of TSLP expression, and the number of tumor-infiltrating mature DCL</pubmed_abstract><journal>Oncoimmunology</journal><pubmed_title>Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma.</pubmed_title><pmcid>PMC5006899</pmcid><funding_grant_id>281987</funding_grant_id><pubmed_authors>Scholer-Dahirel A</pubmed_authors><pubmed_authors>Sastre-Garau X</pubmed_authors><pubmed_authors>Kebir FZ</pubmed_authors><pubmed_authors>Rodriguez J</pubmed_authors><pubmed_authors>Tartour E</pubmed_authors><pubmed_authors>Honorio S</pubmed_authors><pubmed_authors>Le Tourneau C</pubmed_authors><pubmed_authors>Mosseri V</pubmed_authors><pubmed_authors>Pattarini L</pubmed_authors><pubmed_authors>Huerre M</pubmed_authors><pubmed_authors>Nicolas A</pubmed_authors><pubmed_authors>Lappartient E</pubmed_authors><pubmed_authors>Le Peltier N</pubmed_authors><pubmed_authors>Michea P</pubmed_authors><pubmed_authors>Sablin MP</pubmed_authors><pubmed_authors>Berger F</pubmed_authors><pubmed_authors>Ventre A</pubmed_authors><pubmed_authors>Soumelis V</pubmed_authors><pubmed_authors>Klijanienko J</pubmed_authors><pubmed_authors>Jouffroy T</pubmed_authors><pubmed_authors>Sirven P</pubmed_authors><pubmed_authors>Badoual C</pubmed_authors><pubmed_authors>Guillot-Delost M</pubmed_authors><pubmed_authors>Guillere L</pubmed_authors><pubmed_authors>Chouchane-Mlik O</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma.</name><description>Thymic stromal lymphopoietin (TSLP) is an interleukin (IL)-7-like cytokine expressed by epithelial cells during allergic inflammation, and activating dendritic cells (DC). Its expression and functional role in cancer remain controversial. We conducted retrospective (n = 89), and prospective studies including patients with untreated primary head and neck squamous cell carcinoma (HNSCC). We found that TSLP was overexpressed by HNSCC tumor cells, and associated with a highly differentiated status. However, no significant difference in overall and recurrence-free survival was found between patients bearing a tumor with high and low TSLP levels, respectively. Surprisingly, there was no significant association between the levels of TSLP expression, and the number of tumor-infiltrating mature DCL</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Jul</publication><modification>2025-06-01T01:07:29.93Z</modification><creation>2025-06-01T01:07:29.93Z</creation></dates><accession>S-EPMC5006899</accession><cross_references><pubmed>27622034</pubmed><doi>10.1080/2162402X.2016.1179414</doi><doi>10.1080/2162402x.2016.1179414</doi></cross_references></HashMap>